WallStSmart

Becton Dickinson and Company (BDX)vsMiniMed Group, Inc. Common Stock (MMED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 598% more annual revenue ($22.48B vs $3.22B). BDX leads profitability with a 4.2% profit margin vs -9.7%. BDX earns a higher WallStSmart Score of 52/100 (C-).

BDX

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 5.5Value: 5.3Quality: 5.0
Piotroski: 6/9Altman Z: 1.49

MMED

Avoid

33

out of 100

Grade: F

Growth: 6.7Profit: 3.5Value: 5.0Quality: 6.8
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+11.0%)

Margin of Safety

+11.0%

Fair Value

$202.87

Current Price

$180.94

$21.93 discount

UndervaluedFair: $202.87Overvalued

Intrinsic value data unavailable for MMED.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX1 strengths · Avg: 8.0/10
Price/BookValuation
2.0x8/10

Reasonable price relative to book value

MMED3 strengths · Avg: 8.7/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
16.6%8/10

16.6% revenue growth

Areas to Watch

BDX4 concerns · Avg: 3.0/10
P/E RatioValuation
31.2x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
3.9%3/10

ROE of 3.9% — below average capital efficiency

Profit MarginProfitability
4.2%3/10

4.2% margin — thin

EPS GrowthGrowth
-31.4%2/10

Earnings declined 31.4%

MMED4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Operating MarginProfitability
0.2%3/10

Operating margin of 0.2%

Free Cash FlowQuality
$-90.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Price/Book. PEG of 1.11 suggests the stock is reasonably priced for its growth.

Bull Case : MMED

The strongest argument for MMED centers on Debt/Equity, Price/Book, Revenue Growth. Revenue growth of 16.6% demonstrates continued momentum.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin. Thin 4.2% margins leave little buffer for downturns.

Bear Case : MMED

The primary concerns for MMED are EPS Growth, Return on Equity, Operating Margin.

Key Dynamics to Monitor

BDX profiles as a value stock while MMED is a growth play — different risk/reward profiles.

MMED is growing revenue faster at 16.6% — sustainability is the question.

BDX generates stronger free cash flow (509M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BDX scores higher overall (52/100 vs 33/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

MiniMed Group, Inc. Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.

Want to dig deeper into these stocks?